Demographic and treatment characteristics of the 3 study groups
| Characteristic . | HCT, n = 1792 . | Non-HCT, n = 5455* . | DOL, n = 16 340† . | |||
|---|---|---|---|---|---|---|
| . | n . | (%) . | n . | (%) . | n . | (%) . |
| Female | 819 | (45.7) | 2381 | (43.6) | 7 500 | (45.9) |
| Race/ethnicity | ||||||
| White non-Hispanic | 1504 | (83.9) | 4543 | (83.3) | — | — |
| Black | 40 | (2.2) | 202 | (3.7) | — | — |
| Hispanic | 81 | (4.5) | 270 | (4.9) | — | — |
| Asian | 75 | (4.2) | 241 | (4.4) | — | — |
| Other/unknown | 92 | (5.1) | 199 | (3.6) | — | — |
| Age at index date, y‡ | ||||||
| <20 | 277 | (15.5) | 767 | (14.1) | 570 | (3.5) |
| 20-39 | 376 | (21.0) | 934 | (17.1) | 4 100 | (25.1) |
| 40-59 | 843 | (47.0) | 2590 | (47.5) | 8 660 | (53.0) |
| ≥60 | 296 | (16.5) | 1164 | (21.3) | 3 010 | (18.4) |
| Year of index event | ||||||
| 1992-1999 | 520 | (29.0) | 1417 | (26.0) | 4 480 | (27.4) |
| 2000-2009 | 1272 | (71.0) | 4038 | (74.0) | 11 860 | (72.6) |
| Diagnosis category§ | ||||||
| Hematologic malignancy | 1617 | (90.2) | 4808 | (88.1) | — | — |
| Nonhematologic solid tumor | 175 | (9.8) | 647 | (11.9) | — | |
| Donor type | ||||||
| Autologous/isogeneic | 867 | (48.4) | — | — | — | — |
| Related allogeneic | 503|| | (28.1) | — | — | — | — |
| Unrelated allogeneic | 422¶ | (23.5) | — | — | — | — |
| History of total body irradiation | ||||||
| None | 969 | (54.1) | — | — | — | — |
| <10 Gy | 221 | (12.3) | — | — | — | — |
| ≥10 Gy | 602 | (33.6) | — | — | — | — |
| History of cGVHD# | 642 | (36.1) | — | — | — | — |
| History of cancer relapse after index date | 434 | (24.2) | — | — | — | — |
| Died during the follow-up period | 388 | (21.7) | 997 | (18.3) | 581 | (3.6) |
| Characteristic . | HCT, n = 1792 . | Non-HCT, n = 5455* . | DOL, n = 16 340† . | |||
|---|---|---|---|---|---|---|
| . | n . | (%) . | n . | (%) . | n . | (%) . |
| Female | 819 | (45.7) | 2381 | (43.6) | 7 500 | (45.9) |
| Race/ethnicity | ||||||
| White non-Hispanic | 1504 | (83.9) | 4543 | (83.3) | — | — |
| Black | 40 | (2.2) | 202 | (3.7) | — | — |
| Hispanic | 81 | (4.5) | 270 | (4.9) | — | — |
| Asian | 75 | (4.2) | 241 | (4.4) | — | — |
| Other/unknown | 92 | (5.1) | 199 | (3.6) | — | — |
| Age at index date, y‡ | ||||||
| <20 | 277 | (15.5) | 767 | (14.1) | 570 | (3.5) |
| 20-39 | 376 | (21.0) | 934 | (17.1) | 4 100 | (25.1) |
| 40-59 | 843 | (47.0) | 2590 | (47.5) | 8 660 | (53.0) |
| ≥60 | 296 | (16.5) | 1164 | (21.3) | 3 010 | (18.4) |
| Year of index event | ||||||
| 1992-1999 | 520 | (29.0) | 1417 | (26.0) | 4 480 | (27.4) |
| 2000-2009 | 1272 | (71.0) | 4038 | (74.0) | 11 860 | (72.6) |
| Diagnosis category§ | ||||||
| Hematologic malignancy | 1617 | (90.2) | 4808 | (88.1) | — | — |
| Nonhematologic solid tumor | 175 | (9.8) | 647 | (11.9) | — | |
| Donor type | ||||||
| Autologous/isogeneic | 867 | (48.4) | — | — | — | — |
| Related allogeneic | 503|| | (28.1) | — | — | — | — |
| Unrelated allogeneic | 422¶ | (23.5) | — | — | — | — |
| History of total body irradiation | ||||||
| None | 969 | (54.1) | — | — | — | — |
| <10 Gy | 221 | (12.3) | — | — | — | — |
| ≥10 Gy | 602 | (33.6) | — | — | — | — |
| History of cGVHD# | 642 | (36.1) | — | — | — | — |
| History of cancer relapse after index date | 434 | (24.2) | — | — | — | — |
| Died during the follow-up period | 388 | (21.7) | 997 | (18.3) | 581 | (3.6) |
Matched on 3:1 basis by sex and age at and year of HCT/cancer diagnosis compared with HCT survivors. Data on relapse status are not collected by the Washington State Cancer Registry.
Matched on 10:1 basis by sex and age at and year of HCT/driver’s licensing to HCT survivors age ≥16 years at time of transplant. Race/ethnicity data not available.
Age at transplant (HCT survivors), initial cancer diagnosis (non-HCT cancer survivors), or driver’s licensing (general population).
A more detailed breakdown of diagnoses can be found in supplemental Table 1.
Includes 57 individuals who had previously received an autologous transplant.
Includes 20 individuals who had previously received an autologous transplant.
Limited to those who required systemic immunosuppressive therapy (14 with unknown status).